What the FDA labels say about taking them together
Atropine and phenylephrine
Phenylephrine's FDA label of August 19, 2026 names atropine in its drug interactions section; the atropine labels PlainMeds reads (4) do not name phenylephrine. The phenylephrine label: “… and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. …”
Check it at the source: the atropine FDA label on DailyMed (effective May 18, 2026, Hospira, Inc.); the phenylephrine FDA label on DailyMed (effective August 19, 2026, Hikma Pharmaceuticals USA Inc.).
What does the atropine label say about phenylephrine?
Atropine's label (effective May 18, 2026) and its 3 other brand-application labels do not name phenylephrine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atropine Sulfate), Hospira, Inc., effective May 18, 2026 (SPL set ad8916e7-206e-409e-2582-30d072845dd4), via openFDA; the full label on DailyMed
What does the phenylephrine label say about atropine?
Phenylephrine label, drug interactionsDRUG INTERACTIONS Agonistic effects with monoamine oxidase inhibitors (MAOI), β-adrenergic blocking agents, α-2 adrenergic agonists, steroids, tricyclic antidepressants, norepinephrine transport inhibitors, ergot alkaloids, centrally-acting sympatholytic agents and atropine sulfate ( 7.1 ) Antagonistic effects on and by α-adrenergic blocking agents
Phenylephrine Hydrochloride label (Alcon Laboratories, Inc., April 1, 2025), drug interactionsConcomitant use of phenylephrine and atropine may enhance the pressor effects and induce tachycardia in some patients.
Biorphen label (Dr. Reddy's Laboratories Inc., March 31, 2026), drug interactionsDRUG INTERACTIONS Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. ( 7.1 ) Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents.
Source: FDA drug label (Phenylephrine Hydrochloride, NDA207926), Alcon Laboratories, Inc., effective April 1, 2025 (SPL set cacbb3fd-1c03-4523-a1bf-0ccc4be102ef), via openFDA
Source: FDA drug label (Biorphen, NDA212909), Dr. Reddy's Laboratories Inc., effective March 31, 2026 (SPL set 2f715e4e-b269-b935-d2c9-003cb29770be), via openFDA
Source: FDA drug label (Phenylephrine Hydrochloride), Hikma Pharmaceuticals USA Inc., effective August 19, 2026 (SPL set e1a7ab4b-0afe-4463-a039-5be0323cf2f7), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atropine | Phenylephrine | |
|---|---|---|
| Labeled for | n/a | Cough and cold, Allergies |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $7.74 per mL 1% eye drops | $5.24 per mL 10% eye drop |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once